Biocon surges 14% on USFDA approval to biosimilar drug
OnShares of Biocon (BSE -0.87 %) shot up over 14 per cent in Monday’s trade after the USFDA granted marketing approval to its biosimilar drug Trastuzumab. This ends the speculation over the drug’s launch. The scrip was trading 14.20 % higher at…